{"id":"grt-c901","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL6068550","moleculeType":"Small molecule","molecularWeight":"507.65"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GRT-C901 works by inhibiting the main protease of the SARS-CoV-2 virus, which is essential for the virus's replication. This inhibition prevents the virus from producing the proteins necessary for its replication and spread. As a result, GRT-C901 has antiviral properties.","oneSentence":"GRT-C901 is a small molecule that targets the SARS-CoV-2 main protease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:01:18.487Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT05456165","phase":"PHASE2","title":"Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer","status":"WITHDRAWN","sponsor":"Gritstone bio, Inc.","startDate":"2022-05-19","conditions":"Colonic Neoplasms, Colorectal Neoplasms","enrollment":""},{"nctId":"NCT03639714","phase":"PHASE1, PHASE2","title":"A Study of a Personalized Neoantigen Cancer Vaccine","status":"COMPLETED","sponsor":"Gritstone bio, Inc.","startDate":"2019-02-13","conditions":"Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GRT-C901","genericName":"GRT-C901","companyName":"Seattle Project Corporation","companyId":"seattle-project-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GRT-C901 is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}